Zealand Pharma's Dual GLP-1/GLP-2 Agonist Dapiglutide Shows Promising 11.6% Weight Loss at 28 Weeks on June 20, 2025 Clinical Trials Dapiglutide Glucagon-Like Peptide 1 Glucagon-Like Peptide 2 Obesity Safety Weight Loss Zealand Pharma +